Key result
Individualized antiplatelet therapy guided by platelet function testing decreased the risk of MACCE compared with standard therapy in patients after PCI.
Why the study?
It remains controversial whether individualized antiplatelet therapy guided by platelet function test can improve prognosis in patients after PCI.
Does individualized antiplatelet therapy guided by platelet function test reduce major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention?
Meta-Analysis (n=16,835)
Does individualized antiplatelet therapy guided by platelet function test reduce major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention?
Individualized antiplatelet therapy guided by platelet function testing reduces MACCE without increasing bleeding risk in post-PCI patients.
Answers are grounded in this paper and cite their sources.
Supports PFT-guided therapy post-PCI; confirms MACCE benefit in Level 1 meta-analysis.
Platelet function test (PFT) is universally used to assess platelet reactivity to antiplatelet drugs in patients after percutaneous coronary intervention (PCI). However, it remains controversial whether individualized antiplatelet therapy guided by PFT can improve the prognosis in patients after PCI. This meta-analysis was conducted to explore the efficacy and safety of individualized antiplatelet therapy guided by PFT in patients after PCI. Studies that compared PFT-guided antiplatelet therapy with standard antiplatelet therapy were researched. The risks of major adverse cardiovascular and cerebrovascular events (MACCE) and major bleeding events were assessed. Pooled odds ratios (ORs) with 95% CIs were obtained. Finally, a total of 16,835 patients from 22 studies met the criteria and were included in the meta-analysis. Compared with standard antiplatelet therapy, individualized antiplatelet therapy guided by PFT significantly decreased the risk of MACCE (OR: 0.58, 95% CI: 0.43-0.77) in patients after PCI. There was no significant difference in major bleeding events (OR: 0.85, 95% CI: 0.70-1.05, P = 0.13). This study identified that PFT-guided individualized antiplatelet therapy could reduce the incidence of MACCE without increasing the risk of hemorrhage in patients after PCI.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2023) conducted a meta-analysis in percutaneous coronary intervention (n=16,835). Individualized antiplatelet therapy guided by platelet function test (PFT) vs. Standard antiplatelet therapy was evaluated on major adverse cardiovascular and cerebrovascular events (MACCE) (OR 0.58, 95% CI 0.43-0.77). Individualized antiplatelet therapy guided by platelet function testing decreased the risk of MACCE compared with standard therapy in patients after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: